Replimune accelerated cost cuts after the FDA issued a second complete response letter rejecting its advanced melanoma candidate RP1. The company plans layoffs across Massachusetts, cutting 144 employees in Woburn and 80 in Framingham, according to WARN notices. Replimune said the agency’s rejection left it with “no choice” but to eliminate jobs and scale back U.S. manufacturing, a pivot tied to uncertainty about accelerated approval in the absence of a timely path forward. Analysts at BMO Capital Markets characterized the situation as a challenging path that may require additional funding, and suggested the record showed misalignment on the acceptability of a single-arm study design for accelerated approval under the CRL.